Clinical trials: Atorvastatin
Healthy
A Study of LY3502970 in Healthy Participants
The main purposes of this study are to determine: The safety of LY3502970 and any side effects that might be associated with it. How much LY3502970 gets into the bloodstream and how long it takes the body to get rid of it.
- Trial name
- NCT03929744
- Testing
- LY3502970, Atorvastatin, Simvastatin
- Where
- United States
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Vaccine Response
Systems Biological Assessment of Statin Effect on Vaccine Responses
This study is being done to answer the question: Does the use of statin lipid-lowering medication change the effect of influenza vaccine? The research team will use the knowledge gained from answering this question to understand…
- Trial name
- NCT06024096
- Testing
- Atorvastatin, Quadrivalent seasonal influenza vaccine
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Emory University
Cardiovascular Diseases
Impact of Statin Therapy on Adaptations to Aerobic Exercise
The purpose of this study is to determine how different doses of a statin affect muscle health and exercise.
- Trial name
- NCT03360916
- Testing
- Lipitor 20Mg Tablet, Lipitor 80Mg Tablet, Exercise Program
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Endometriosis
MicroRNA Activation of LOX-1 Mechanisms in Endometriosis
Endometriosis is a disorder that occurs in women. With endometriosis, tissue that should be found in the womb is found in sites outside of the womb.
- Trial name
- NCT05331053
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Penn State University
Mitochondrial Diseases
Impact of Statin Therapy on Muscle Mitochondrial Function and Aerobic Capacity
The purpose of this study is to test how different doses of a statin, Lipitor, affect muscle health and function, and cardiovascular fitness.
- Trial name
- NCT03351998
- Testing
- Lipitor 20Mg Tablet, Lipitor 80Mg Tablet
- Where
- 2 sites in United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Type 2 Diabetes
CHOlesterol Lowering and Residual Risk in Type 2 Diabetes
The purpose of this study is to investigate why individuals with type 2 diabetes are at increased risk for heart disease and stroke.
- Trial name
- CHORD (NCT04369664)
- Testing
- Statin, PCSK9 inhibitor, Ezetimibe 10mg
- Where
- United States
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Healthy Adults
STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS
The purpose of this study is to characterize the effect of PF-06882961, administered at 2 steady-state dose levels, on the PK of single doses of atorvastatin (20 mg) or midazolam (5 mg), administered separately, in healthy adult…
- Trial name
- NCT05093205
- Testing
- PF-06882961, Atorvastatin, Midazolam
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study of LY3478045 in Healthy Participants
The main purpose of this study in healthy participants is to learn more about the safety of LY3478045 and any side effects that might be associated with it.
- Trial name
- NCT04270370
- Testing
- LY3478045, Atorvastatin
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis
Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants
The primary objective of this study is to evaluate the effect of filgotinib on a mixed organic anion transporting polypeptide/cytochrome P450 3A (OATP/CYP3A), OATP/ breast cancer resistance protein (BCRP), and OATP substrates…
- Trial name
- NCT04608344
- Testing
- Atorvastatin, Pravastatin, Rosuvastatin
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Cardiovascular Diseases, Myocardial Infarction
Subclinical Cardiovascular Disease in Psoriatic Disease
This study will look at how chronic inflammation seen in psoriatic disease translates into the increased atherosclerotic and thrombotic risk and how treatment reduces this CVD risk.
- Conditions
- Cardiovascular Diseases, Myocardial Infarction, Atherosclerotic Cardiovascular Disease, Thrombotic Vascular Disease
- Trial name
- NCT03228017
- Testing
- Aspirin and/or Atorvastatin
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Dyslipidemias
A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia
The purpose of this two-part study is to evaluate the safety and tolerability of the study drug known as LY3202328 in healthy overweight participants in Part A, and those with dyslipidemia (abnormal blood fats) in Part B.
- Trial name
- NCT02714569
- Testing
- LY3202328, Atorvastatin, Simvastatin
- Where
- 4 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Hyperlipidemia, Insulin Resistance
Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling
Background: There is general agreement that statin-treatment of patients to lower plasma cholesterol levels can increase the incidence of type 2 diabetes mellitus (T2D) in some individuals1-5.
- Conditions
- Hyperlipidemia, Insulin Resistance, Type 2 Diabetes
- Trial name
- NCT02437084
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Stanford University
Hypercholesterolemia
Bioequivalence Study Comparing A New 10 Mg Atorvastatin Tablet To A 10 Mg Atorvastatin Commercial Tablet
To determine whether new 10 mg atorvastatin tablets are bioequivalent to 10 mg commercial atorvastatin tablets (Lipitor®).
- Trial name
- NCT00917579
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypercholesterolemia
Bioavailability Study for New Atorvastatin Formulation
The purpose of this study is to estimate the relative bioavailability of the commercial tablet with one prototype extemporaneous preparation suspension formulation, to assist with internal decision making on formulation…
- Trial name
- NCT00844376
- Testing
- Atorvastatin suspension, Lipitor
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypercholesterolemia
Bioequivalence Study Comparing A New 80 Mg Atorvastatin Tablet To A 80 Mg Atorvastatin Commercial Tablet
To determine whether new 80 mg atorvastatin tablets are bioequivalent to 80 mg commercial atorvastatin tablets (Lipitor®).
- Trial name
- NCT00917644
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypercholesterolemia
Actual Use Trial of Atorvastatin Calcium 10 mg
The purpose of this actual use study is to simulate the over the counter use of atorvastatin calcium 10 mg.
- Trial name
- NCT01964326
- Testing
- Atorvastatin calcium 10 mg
- Where
- 37 sites in United States
- Volunteers
- 1,311 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Effect of Atorvastatin on the Pharmacokinetics of Lomitapide
Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Lomitapide in Healthy Subjects.
The primary objective of this study is to assess the effect of atorvastatin, a weak cytochrome P450 (CYP) 3A4 inhibitor, on the pharmacokinetics (PK) of lomitapide and its 2 primary metabolites, M1 and M3.
- Trial name
- NCT02080455
- Testing
- lomitapide, Atorvastatin
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Aegerion Pharmaceuticals, Inc.
Renal Insufficiency
Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)
The purpose of this open-label, 2-period, fixed-sequence study is to characterize the plasma pharmacokinetic profiles of midazolam, dabigatran, pitavastatin, atorvastatin, and rosuvastatin following a single oral dose…
- Trial name
- NCT03311841
- Testing
- Midazolam oral solution, Dabigatran and pitavastatin oral solution, Atorvastatin and rosuvastatin oral solution
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Volunteer
A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers
A single-center, crossover study to evaluate the pharmacokinetics of dalcetrapib and atorvastatin from prototype fixed dose combination formulations in healthy volunteers.
- Trial name
- NCT01363999
- Testing
- atorvastatin, dalcetrapib
- Where
- New Zealand
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Insulin-Dependent, Hypercholesterolemia
Statins in Children With Type 1 Diabetes and Hypercholesterolemia
Children with type1 diabetes (T1DM) have increased risk for cardiovascular disease (CVD) due to chronic increase in the blood sugars and inflammation.
- Trial name
- NCT01236365
- Testing
- Atorvastatin
- Where
- 5 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Nemours Children's Clinic